Susceptible or immune? CMV T-cell immunity accurately predicts patient status

In this presentation, Steve Kleiboeker (Vice-President of Research and Development at Viracor Eurofins; MO, USA) discusses CMV diagnostic testing, in particular the CMV T-cell immunity panel, which can help physicians predict which patients are at risk and be prepared to work with the patients pre-emptively before they develop the disease.

To learn more about T-cell immunity monitoring and assay development, watch this presentation filmed at the 3rd World Vaccine and Immunotherapy Congress (2 December 2019, San Francisco; CA, USA).

More on the CMV T-cell immunity panel

• Consensus guidelines recommend antiviral prophylaxis in lung (and other high-risk solid organ transplants) recipients who are R+ or who receive an organ from a seropositive donor (D+/R-)
• The high cost of antiviral treatments, risk of bone marrow suppression and potential development of subsequent viral resistance, make the optimal duration of prophylaxis controversial.
• There is an unmet clinical need to more precisely determine post-transplantation risk for CMV beyond D/R serostatus, with the goal of tailoring CMV prophylaxis duration to an individual’s CMS disease specific risk.
• Since T-cell responses are critical to CMV immune control, assays to measure T-cell responses to MCV antigens may predict future infections.

Viracor Eurofins offers comprehensive CMV testing to help detect infection, evaluate T-cell response and assess antiviral resistance for improved patient outcomes. To find out more visit: https://www.viracor-eurofins.com/biopharma-services/